Beijing Yuanqi Zhiyao Technology

Meta-Origin (Beijing Yuanqi Zhiyao Technology) is a China-based biotechnology company dedicated to discovering novel small molecule therapeutics for challenging, "undruggable" targets. The company utilizes a proprietary AI-driven platform that integrates structural biology, medicinal chemistry, and advanced computational algorithms to streamline the drug discovery process. Founded in 2021 by Dr. Ding Sheng, a renowned scientist and Dean at Tsinghua University, Meta-Origin focuses on therapeutic areas with significant unmet needs, including oncology and metabolic disorders. The firm has attracted investment from prominent venture capital groups like Matrix Partners China and IDG Capital to advance its internal pipeline and technological capabilities.